The Dynamic Roles of TGF-β Signalling in EBV-Associated Cancers

Sharmila Velapasamy 1, Christopher W. Dawson 2, Lawrence S. Young 3 *, Ian C. Paterson 1,4 and Lee Fah Yap 1,4, *

1 Department of Oral & Craniofacial Sciences, Faculty of Dentistry, University of Malaya, 50603 Kuala Lumpur, Malaysia; vsharmila84@gmail.com (S.V.); ipaterson@um.edu.my (I.C.P)
2 Institute of Cancer and Genomic Medicine, University of Birmingham, Birmingham B15 2TT, UK; c.w.dawson@bham.ac.uk
3 Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK; L.S.Young@warwick.ac.uk
4 Oral Cancer Research and Coordinating Centre, University of Malaya, 50603 Kuala Lumpur, Malaysia
* Correspondence: yapleefah@um.edu.my; Tel.: +60-3-7967-6471; Fax: +60-3-7967-6456

Received: 9 July 2018; Accepted: 25 July 2018; Published: 27 July 2018

Abstract: The transforming growth factor-β (TGF-β) signalling pathway plays a critical role in carcinogenesis. It has a biphasic action by initially suppressing tumorigenesis but promoting tumour progression in the later stages of disease. Consequently, the functional outcome of TGF-β signalling is strongly context-dependent and is influenced by various factors including cell, tissue and cancer type. Disruption of this pathway can be caused by various means, including genetic and environmental factors. A number of human viruses have been shown to modulate TGF-β signalling during tumorigenesis. In this review, we describe how this pathway is perturbed in Epstein-Barr virus (EBV)-associated cancers and how EBV interferes with TGF-β signal transduction. The role of TGF-β in regulating the EBV life cycle in tumour cells is also discussed.

Keywords: TGF-β signalling; Epstein-Barr virus; nasopharyngeal carcinoma; gastric cancer; B-cell lymphoma

1. Introduction

The transforming growth factor-beta (TGF-β) superfamily is a group of multifunctional proteins comprising more than 40 members that are clustered in several subfamilies, which include TGF-β, activins/inhibins, bone morphogenetic proteins (BMPs), nodal and growth differentiation factors (GDFs) [1,2]. The prototypic member, TGF-β1, is produced by a diverse range of cell types and modulates cell proliferation, migration, adhesion, differentiation and survival [2,3]. Consequently, a malfunctioning TGF-β pathway is central to many diseases including cancer. TGF-β functions as a tumour suppressor by inhibiting the growth of untransformed epithelial, endothelial and lymphoid cells [4–6] and resistance to TGF-β is regarded as one of the crucial steps in malignant progression [2,7]. In the early stages of cancer development, TGF-β signalling functions as a tumour suppressor by inhibiting cell cycle progression from G1 to S phase and inducing apoptosis, senescence and differentiation [2,5,8,9]. Conversely, in late stage disease, it acts as a tumour promoter by inducing epithelial-to-mesenchymal transition (EMT), migration, invasion, metastasis, angiogenesis and immune suppression [2,9–12]. Frequently, cancer cells become resistant to the tumour suppressive effects of TGF-β, however functional TGF-β signalling often persists in these cells enabling TGF-β-induced tumour promoting phenotypes [13–16]. Accumulating evidence has revealed that the TGF-β signalling pathway is targeted by many oncogenic viruses, including Epstein-Barr virus (EBV), during the course of tumorigenesis [17].
EBV was the first human cancer virus to be discovered [18] and the most common viral infection in humans. Following its discovery in Burkitt lymphoma (BL), EBV has been linked to the aetiology of multiple human cancers of both lymphoid and epithelial origin, including classical Hodgkin lymphoma (HL), diffuse large B cell lymphoma (DLBCL), post-transplant lymphoproliferative disorders (PTLD), nasopharyngeal carcinoma (NPC) and EBV-associated gastric cancer (EBVaGC) [19]. Here, we provide an overview of our current understanding of the dynamic roles that TGF-β plays in EBV-associated malignancies.

2. TGF-β Signalling

In mammals, there are three TGF-β isoforms (TGF-β1, TGF-β2 and TGF-β3), each encoded by different genes [20–22]. These isoforms are highly similar and share approximately 70–80% sequence homology [22–24]. TGF-β1 was the first isoform to be characterized and is the most studied to date [20,21]. TGF-β1 is synthesized in a latent form as a large precursor protein which binds to and is stored in the extracellular matrix (ECM) [25]. The precursor protein undergoes proteolytic digestion by the endopeptidase furin to produce two proteins, namely latency-associated peptide (LAP; 278 amino acids) and mature TGF-β1 (112 amino acids) [26,27]. Despite the cleavage of the precursor protein, the LAP remains bound to the mature TGF-β1 making the TGF-β1 biologically inactive [28]. The release of active TGF-β1 from the ECM can be triggered by several factors, such as changes in the cellular environment, tissue injury or inflammation [29–31]. Activated TGF ligands mediate signalling through the TGF-β type I and type II receptors (TGFR-1 and TGFR-2, respectively) that are endowed with serine/threonine kinase activity [32,33]. Upon binding of an active TGF-β ligand to TGFR-2, TGFR-1 is recruited and phosphorylated by TGFR-2. The activated heterotetramer TGFR-1/TGFR-2 complex triggers the canonical Smad-dependent, as well as non-canonical Smad-independent signalling pathways (Figure 1).

Figure 1. The TGF-β signalling pathway. Binding of an activated TGF-β ligand to TGFR-2 recruits and activates TGFR-1. This, in turn, phosphorylates Smad2 and/or Smad3 (R-Smads), which then form complexes with Smad4 (Co-Smad) and translocate into nucleus to regulate the transcription of various target genes. Smad7 (I-Smad) inhibits the pathway through various mechanisms, including mediating the degradation of TGFR-1, inhibiting phosphorylation of Smad2/Smad3 or inhibiting the formation of the Smad2/3-Smad4 complex. In addition to the canonical Smad-dependent signalling, activated TGF-β receptors can trigger other signalling pathways including ERK-MAPK, p38-MAPK, PI3K-Akt and JNK.
2.1. Canonical Smad-Dependent Signalling

Smad proteins were the first identified downstream signalling transducers of TGF-β [34]. The proteins of the SMAD family are the vertebrate homologs of the *Drosophila* mothers against decapentaplegic (MAD) protein and the *Caenorhabditis elegans* small body size (SMA) protein [35,36]. These proteins are divided into three groups based on their functions: receptor-activated Smads (R-Smads; Smad2 and Smad3), common mediator Smad (Co-Smad; Smad4) and inhibitory Smads (I-Smads; Smad6 and Smad7) [37–39]. Following TGF-β binding to TGFR-2 and receptor activation, the Smad anchor for receptor activation (SARA) protein binds TGFR-1 and Smad2 and/or Smad3 simultaneously, resulting in the phosphorylation of the Smad2 and/or Smad3 by TGFR-1 [40–42]. Upon activation, Smad2 and/or Smad3 are released from the receptor complex and SARA, and oligomerize with Smad4 through their MH2 domains [40,42,43]. The Smad2/Smad4 and/or Smad3/Smad4 complexes then translocate to the nucleus to either stimulate or repress the transcription of their target genes, depending on interactions with various transcription factors [44]. A variety of transcription factor families have been identified that act in concert with Smad proteins, including p300/CBP, AP1, and Forkhead [45–47].

The two I-Smads, Smad6 and Smad7, tightly control the activation of TGF-β signalling. Compared to Smad6, Smad7 has been shown to inhibit TGF-β signalling more efficiently through a number of mechanisms [48,49]. These include inhibition of the phosphorylation of R-Smads by forming a complex with activated TGFR-1, degradation of the activated TGFR-1 by recruiting ubiquitin E3 ligases, such as Smurf1/2 or disruption of the formation of functional Smad-DNA complexes in the nucleus [50–53]. Recent evidence also demonstrated that Smad7 might directly oligomerize with R-Smads and inhibit their activities [54].

2.2. Non-Canonical Smad-Independent Signalling

While the canonical Smad-dependent pathway has been regarded as the major signalling route of TGF-β, the ligand can also signal through non-canonical Smad-independent pathways, engaging the ERK-MAPK, p38-MAPK, PI3K-AKT and JNK pathways [1,2]; different mechanisms are utilised to trigger these signalling pathways. For example, activation of the ERK-MAPK pathway is mediated by the phosphorylation of TGFR-1, whereas the activation of both TGFR-1 and TGFR-2 are required for activation of the PI3K-AKT signalling pathway [55–57]. Notably, activation of the canonical Smad-dependent and the non-canonical Smad-independent signalling pathways is not mutually exclusive [58,59]. In breast cancer cells lines, for example, both pathways act together to mediate TGF-β-induced growth arrest [59].

3. Resistance of EBV-Positive Cells to TGF-β-Mediated Cytostasis

In normal epithelial and neuronal cells, TGF-β1 inhibits progression from G1 to S phase of the cell cycle by inducing the expression of CDK inhibitors, p15 and p21, thereby blocking the phosphorylation of the Rb protein [60–62]. In addition, the increase in p15 levels induces the release of p27 from CDK4 and/or CDK6 [60]. p21 and the free p27 bind to CDK2, inhibiting formation of cyclin A-CDK2 and/or cyclin E-CDK2, thereby blocking the progression to S phase [60,62]. Further, TGF-β1 suppresses the expression of the c-MYC protein, preventing c-MYC from inhibiting the expression of p15, p21 and p27 [63–65]. This safeguards the induction of the CDK inhibitors and thereby leads to G1 cell cycle arrest. Additionally, TGF-β1 has been shown to induce both the intrinsic and extrinsic apoptotic programs in a cell-type dependent manner [2]. In lymphoma cells, TGF-β1 induces the intrinsic apoptotic pathway by stimulating the expression of several pro-apoptotic Bcl-2 family members (such as Bmf, Bim and Bax), which in turns suppress the expression of anti-apoptotic proteins (Bcl-XL and Bcl-2) [66]. The ability of TGF-β1 to induce the extrinsic apoptotic program has been shown in liver and lung cancer cells, in which expression of death-associated protein kinase (DAPK) and Fas-mediated apoptosis was increased upon the exogenous addition of TGF-β1, respectively [67,68].
EBV-positive and -negative B cells exhibit differential responses to TGF-β. EBV-negative B cells are sensitive to TGF-β-mediated growth inhibition and apoptosis [69–71], whilst these responses are lost in EBV-positive B cells [72–74]. Similarly, gastric tissue-derived EBV-infected epithelial cell lines (GT38 and GT39) have been shown to be resistant to TGF-β1-mediated growth inhibition and apoptosis, as opposed to a TGF-β1-responsive EBV-negative gastric carcinoma cell line HSC-39 [75]; similar observations were also obtained in our laboratory with the EBV-positive NPC cell line, C666-1 (Yap L.F.; Dawson C.W. (University of Malaya, Kuala Lumpur, Malaysia) Personal observation, 2013). However, the growth of an EBV-negative NPC cell line CNE-2 was not suppressed by exogenous TGF-β1 [76]. CNE-2 cells were originally derived from a poorly differentiated NPC which was likely to be EBV-positive [77]. Although CNE-2 cells do not carry EBV genomes in long-term culture, it is possible that these cells developed resistance towards the cytostatic effect of TGF-β at the initial stage of EBV infection and retained this characteristic even after they lost the EBV genomes. It is reasonable to hypothesize that EBV-infected cells can selectively outgrow the neighboring cells (EBV-negative) which are growth inhibited by TGF-β1 produced by EBV-infected cells through the expression of Zta (discussed below). Such EBV-infected cells can then clonally expand to drive the transformation process. Indeed, it was shown that LMP1-transfected BALB/c 3T3 cells exhibited non-transformed phenotypes in vitro but those that lost sensitivity to TGF-β1-mediated growth inhibition formed tumours in severe combined immunodeficiency (SCID) mice [78], implying that loss of TGF-β responsiveness is a critical event for the tumorigenicity of EBV-infected cells.

3.1. Contribution of EBV Latent Genes

EBV displays two distinct lifecycles, namely the lytic and latent cycles. The lytic cycle is associated with viral replication in which new virions are produced while latent cycle is a state of persistent infection and the absence of productive viral replication [79]. During latent infection, a limited set of EBV genes is expressed and to date, three latency programmes have been identified. Different types of malignancies are associated with a distinct latency programme (Table 1). The EBV lytic cycle is initiated by the expression of the viral immediate-early gene BZLF1 (the gene product is commonly known as Zta or ZEBRA) [80]. While the lytic cycle can be triggered in vitro by diverse stimuli such as phorbol ester and sodium butyrate [81], this process is closely associated with the differentiation of both B cells and epithelial cells in vivo [82–84].

| Malignancy                              | %EBV+ Cases | Latency | EBV Latent Genes                      |
|-----------------------------------------|-------------|---------|---------------------------------------|
| Endemic Burkitt Lymphoma                | 100%        | I       | EBNA1, EBER1, EBER2, BARTs, miR-BARTs |
| Sporadic Burkitt Lymphoma               | 10–85%      |         |                                       |
| HIV-associated Burkitt Lymphoma         | 30–40%      |         |                                       |
| T/NK cell lymphoma                      | 100%        | II      | EBNA1, LMP1, LMP2A, EBER1, EBER2, BARTs, miR-BARTs |
| Hodgkin’s Lymphoma (80–90%)             |             |         |                                       |
| Hodgkin’s Lymphoma (15–20%)             |             |         |                                       |
| HIV-associated Hodgkin’s Lymphoma       | <90%        |         |                                       |
| Diffuse large B-cell lymphoma (Pythorax lymphoma) | 100%        | II/III  | EBNA1, LMP1, LMP2A, EBER1, EBER2, BARTs, miR-BARTs and/or EBNA2, 3A, 3B, 3C, LP |
| Diffuse large B-cell lymphoma (in Elderly patients) | >50%        |         |                                       |
| Diffuse large B-cell lymphoma (late post-transplant) | >50%        |         |                                       |
| HIV-associated diffuse large B-cell lymphoma | 30%        |         |                                       |
Table 1. Cont.

| Malignancy | %EBV+ Cases | Latency | EBV Latent Genes |
|------------|-------------|---------|-----------------|
| Post-transplant B-lymphoproliferative disorder | 100% | III | EBNA 1, 2, 3A, 3B, 3C, LP, LMP1, LMP2A, LMP2B, EBER1, EBER2, BARTs, miRNAs-BARTs, BHRF1 |
| HIV-associated B-lymphoproliferative disease | 100% | II | EBNAl, LMP1, LMP2A, EBER1, EBER2, BARTs, miR-BARTs, BARF1 |
| Nasopharyngeal carcinoma | 98% | II | EBNA1, LMP1, LMP2A, EBER1, EBER2, BARTs, miR-BARTs, BARF1 |
| EBV-associated gastric cancer | 10% | II | EBNA1, LMP1, LMP2A, EBER1, EBER2, BARTs, miR-BARTs, BARF1 |

Epstein-Barr nuclear antigens (EBNA), Latent membrane proteins (LMP), Epstein-Barr virus-encoded RNAs (EBERs), BamHI-A fragment transcripts (BARTs), BamHI fragment H rightward open reading frame 1 (BHRF1). Table adapted from Rickinson [85] and Yap & Lo [86].

It has been shown that the EBV oncoprotein LMP1 was responsible for mediating resistance to the cytostatic effects of TGF-β1 in BL cells (BL41) by elevating levels of cyclin D2 [73]. A modest sensitization to TGF-β was observed in EBV-positive lymphoblastoid cell lines (LCLs) following treatment with LMP1 antisense oligodeoxynucleotides [87], although studies of EBV-converted and stably transfected BL cell lines have shown that LMP1 was not sufficient or necessary to block the TGF-β1 response [88]. Using epithelial cells as study models, LMP1 has been shown to abrogate TGF-β signalling through NF-κB-dependent depletion of transcriptional coactivators required for Smad-mediated transcription [89,90]. Additional evidence showed that LMP1 induction of Id1 through suppression of ATF3 (a SMAD-induced transcriptional repressor) attenuated TGF-β-Smad-mediated transcription and counteracted the cytostatic action of TGF-β1 in epithelial cells [91]. The ability of LMP1 to suppress Smad-dependent transcription was also demonstrated in SCC12F epithelial cells [92]. Further, it has been shown that LMP1 can down-regulate the expression of limb-bud and heart (LBH) resulting in the alleviation of TGF-β1-induced NF-κB signalling inhibition, rendering NPC cells refractory to TGF-β1-mediated cytostasis [93].

Other EBV-encoded proteins have also been shown to repress TGF-β signalling and this could facilitate the evasion of TGF-β-mediated cytostatic effects during EBV infection. In BL Ramous cells and gastric carcinoma cells (HSC-39), LMP2A has been shown to inhibit TGF-β1-induced apoptosis through the PI3K/AKT pathway [94]. A negative feedback loop between EBNA1 and TGF-β was also postulated, in which expression of EBNA1 in a nasopharyngeal adenocarcinoma cell line, AdAH, has been shown to repress TGF-β1-induced transcription by increasing Smad2 protein turnover [95], an effect that may overcome the ability of TGF-β to repress the Q promoter (Qp), which is responsible for EBNA1 expression in NPC [96]. The strategic inhibition of B-cell apoptosis is central to EBV biology. In germinal centres, only those B-cells that express the highest-affinity immunoglobulins are rescued from stringent pro-apoptotic pathways that signal through TGF-β1, FAS and B-cell receptors [97–99]. The ability of EBNA1 to disable TGF-β signalling was also demonstrated in HL cells, where EBNA1 increased Smad2 protein degradation which subsequently inhibited transcription of the TGF-β target gene, PTPRK tumour suppressor, contributing to the growth and survival of HL cells [100]. In B-cells exhibiting a group III latency program, EBNA2 antagonized the apoptotic effects of TGF-β1, partly by repressing the pro-apoptotic “sensitizer” protein, BIK, resulting in B-cell survival [101,102]. Further, BARF1 was found to promote gastric cancer cell proliferation through a mechanism involving the downregulation of Smad4 via an increase in NF-κB-dependent miR-146a [103]. Taken together, it is apparent that TGF-β signalling is disrupted by EBV-encoded latent genes by a variety of mechanisms leading to malignant transformation.

3.2. Dysregulation of TGF-β Receptors

In order to evade the tumour suppressive effects of TGF-β1, cancer cells often develop genetic abnormalities within key molecules of the TGF-β signalling pathway, particularly the TGF-β receptors, TGFBR1 and TGFBR2. However, the contribution of alterations in TGF-β receptor expression to the loss of responsiveness towards TGF-β1-mediated growth inhibition in EBV-positive cells is inconclusive.
some studies showed that the levels of \( TGFBR1 \) and \( TGFBR2 \) did not correlate with resistance [73,75,78], others reported that the lack of responsiveness appeared to correlate with a down-regulation of \( TGFBR2 \) expression [88,104]. These observations suggest that multiple mechanisms regulate the growth inhibitory response to TGF-\( \beta \) in EBV-positive cells. Nonetheless, alterations in the expression of TGF-\( \beta \) receptors have been shown in EBV-associated cancers in vivo. The down-regulation of TGF-\( \beta \) receptors in cancer cells can be caused by multiple mechanisms. For example, the expression of \( TGFBR2 \) can be reduced by mutation, promoter hypermethylation or miRNA regulation. It is noteworthy that TGF-2 expression has been suggested as a positive prognostic marker in DLBCL patients [105]. Further, the mRNA and/or protein levels of \( TGFBR1 \) and \( TGFBR2 \) were found to be significantly reduced in primary NPC tissues compared with non-cancerous controls, and their decreased expression correlated with poor survival [106–109]. However, a recent report described contradictory results in which TGF-1 was found to be up-regulated in primary NPC tissues [110]. We previously had reported the expression of TGF-2 in oral cancer by immunohistochemical analysis [111] and accurate staining results could only be achieved by applying stringent methodologies and assessment. The discrepancy between studies could be due to differences in antibody specificities. It is worth noting that \( TGFBR2 \) is located at chromosome 3p, a region with the most frequent loss of heterozygosity in NPC [112,113], implying that \( TGFBR2 \) might be a tumour suppressor gene that is altered in the early stages of NPC pathogenesis. Using advanced next-generation sequencing technology, several studies have reported genetic abnormalities of key molecules within the TGF-\( \beta \) pathway, including the TGF-\( \beta \) receptors, in EBV-associated cancers (Table 2). Although the frequency of the genetic alterations appears to be low, further studies are warranted to confirm the results and investigate the functional significance of these alterations. It is important to recognize, however, that these results do not take into account possible transcriptional alterations of the receptors and/or signalling molecules.

The involvement of cellular miRNAs in the disruption of TGF-\( \beta \) signalling has also been reported. For example, miR-93 and miR-19a, paralogues of the oncogenic miR-17-92 cluster, were shown to promote NPC aggressiveness by down-regulating TGFR-2 [108,109]. Several studies on global miRNA profiling in NPC have identified a number of differentially expressed miRNAs that target the TGF-\( \beta \) pathway [114–116], but the exact targets within the pathway are yet to be identified. Notably, a susceptibility gene TNFRSF19 in NPC, was shown to render NPC cells resistant to TGF-\( \beta \)-mediated cell cycle arrest [117]. TNFRSF19 was highly expressed in NPC and binds specifically to the kinase domain of TGFR-1, thereby blocking Smad2/3 association with TGFR-1 and subsequent signal transduction.
Table 2. Genetic alterations of TGF-β pathway components in EBV-associated cancers identified by next-generation sequencing.

| Cancer   | Total Number of Cases | EBV Status          | Genes       | Alterations     | Number of Cases with Alterations | References |
|----------|-----------------------|---------------------|-------------|-----------------|----------------------------------|------------|
| NPC      | 56 primary tumours    | Positive            | SMAD3       | Missense mutation | 1 (primary tumour)               | [118]      |
| NPC      | 51 primary tumours    | Positive            | TGF-β1      | Missense mutation | 1 (primary tumour)               | [119]      |
| NPC      | 51 primary tumours    | Positive            | TGF-β2      | Missense mutation | 1 (primary tumour)               | [119]      |
| NPC      | 3 local metastatic tumours | Positive | TGFR2       | Missense mutation | 1 (primary tumour)               | [119]      |
| NPC      | 78 primary tumours    | Positive            | TGF-β1      | Missense mutation | 1 (primary tumour)               | [120]      |
| NPC      | 11 local recurrent tumours | Positive | TGF-β1      | Silent mutation   | 1 (primary tumour)               | [120]      |
| NPC      | 22 distant metastatic tumours | Positive | TGF-β2      | Frame shift deletion | 1 (local recurrent tumour)        | [120]      |
| NPC      | 77 primary tumours    | Positive            | TGFBR1      | Missense mutation | 1 (primary tumour)               | [120]      |
| NPC      | 11 local recurrent tumours | Positive | TGFBR2      | Inter chromosomal translocation | 1 (primary tumour)               | [120]      |
| NPC      | 22 distant metastatic tumours | Positive | SMAD3       | Silent mutation   | 1 (local recurrent tumour)        | [120]      |
| NPC      | 78 primary tumours    | Positive            | SMAD4       | Missense mutation | 1 (primary tumour)               | [120]      |
| NPC      | 11 local recurrent tumours | Positive | SMAD4       | Nonsense mutation | 1 (primary tumour)               | [120]      |
| NPC      | 22 distant metastatic tumours | Positive | SMAD7       | Missense mutation | 1 (local recurrent tumour)        | [120]      |
| EBVaGC   | 134 primary tumours   | Positive: n = 34, Negative: n = 100 | TGFBR1      | Nonsynonymous mutation | 9 (EBV-positive) 8 (EBV-negative) | [121]      |
| AGS cell line | Before and after EBV infection | | | | | |
| EBVaGC   | 22 primary tumours    | Positive            | SMAD4       | Missense mutation | 2                                | [122]      |
| HL       | 7 cell lines          | Positive: L591, Negative: SUPHD1, L540, L428, L1256, KMH2, DEV | SMAD9       | Missense mutation | 1 (KMH2)                        | [123]      |
| HL       | 5 cell lines          | Negative (HDML2, KMH2, UH01, L540, L428) | TGF-β1      | Amplification     | 2 (L540, L428)                  | [124]      |
| HL       | 5 cell lines          | Negative (HDML2, KMH2, UH01, L540, L428) | TGF-β2      | Amplification Deletion | 3 (KMH2, L540, L428) 1 (UH01) | [124]      |
|          |                       |                     | TGFR2       | Amplification     | 3 (KMH2, L540, L428)            | [124]      |
Table 2. Cont.

| Cancer | Total Number of Cases | EBV Status | Genes | Alterations | Number of Cases with Alterations | References |
|--------|-----------------------|------------|-------|-------------|----------------------------------|------------|
| DLBCL  | • 73 primary tumours  | Unreported | TGFBR3 | Amplification | 2 (KMH2, L428)                  |            |
|        | • 21 DLBCL cell lines |            | SMAD1  | Amplification | 3 (KMH2, L540, L428)              |            |
|        |                        |            |        | Deletion     | 2 (HDML2, UM01)                  |            |
|        |                        |            | SMAD5  | Amplification | 3 (KMH2, L540, L428)              |            |
|        | • 73 primary tumours  | Unreported | TGF-β1 | Missense mutation | 1 (primary tumours)          | [125]      |
|        | • 21 DLBCL cell lines |            | TGF-β1 | Intronic mutation | 1 (primary tumours)          |            |
|        |                        |            | TGFBR2 | Intronic mutation | 2 (primary tumours)          |            |
|        |                        |            | TGFBR3 | Intronic mutation | 2 (primary tumours)          |            |
|        |                        |            | SMAD9  | Intronic mutation | 1 (primary tumours)          |            |
| DLBCL  | 51 primary tumours &  | Unreported | TGF-β1 | CNA         | 3 (treated tumours)              |            |
|        | immunochemo-therapy-   |            |        |             |                                   |            |
|        | treated tumours        |            |        |             |                                   |            |
| DLBCL  | 6 refractory & 7        | Negative   | TGFBR2 | Missense mutation | 1 (refractory tumour)        | [127]      |
|        | responsive tumours to   |            |        |             |                                   |            |
|        | R-Chop                 |            |        |             |                                   |            |
| DLBCL  | • 47 relapsed/        | Unreported | TGFBR2 | Missense mutation | 6 (relapsed/refractory tumours) | [128]      |
|        | refractory tumours     |            |        |             |                                   |            |
|        | • 65 primary tumours   |            |        |             |                                   |            |
|        | 295 activated B-cell   | Unreported | TGF-β1 | Missense mutation | 5 (4 ABC, 1 GCB)              | [129]      |
|        | like DLBCL (ABC)       |            |        | Truncated mutation | 2 (ABC)                        |            |
|        | • 164 germinal-center |            | TGF-β2 | Truncated mutation | 2 (1 ABC, 1 GCB)              |            |
|        | B-cell like DLBCL (GCB) |            |        |             |                                   |            |
|        | • 115 unclassified     |            | TGF-β3 | Missense mutation | 1 (ABC)                        |            |
|        | DLBCL                  |            |        |             |                                   |            |
|        |                        |            | TGFBR1 | Missense mutation | 1 (GCB)                        |            |
|        |                        |            | TGFBR2 | Missense mutation | 2 (1 ABC, 1 GCB)              |            |
|        |                        |            |        | Truncated mutation | 2 (1 GCB, 1 unclassified)     |            |
|        |                        |            | TGFBR3 | Missense mutation | 2 (1 ABC, 1 unclassified)      |            |
|        |                        |            |        | Truncated mutation | 1 (GCB)                        |            |
|        |                        |            | SMAD1  | Missense mutation | 1 (ABC)                        |            |
|        |                        |            |        | Truncated mutation | 1 (GCB)                        |            |
|        |                        |            | SMAD2  | Missense mutation | 3 (1 ABC, 1 GCB, 1 unclassified) |            |
|        |                        |            | SMAD4  | Missense mutation | 3 (2 ABC, 1 unclassified)      |            |
|        |                        |            |        | Truncated mutation | 1 (ABC)                        |            |
|        |                        |            | SMAD5  | Missense mutation | 5 (4 ABC, 1 GCB)              |            |
|        |                        |            | SMAD6  | Missense mutation | 1 (GCB)                        |            |
|        |                        |            | SMAD7  | Missense mutation | 2 (1 ABC, 1 GCB)              |            |
|        |                        |            | SMAD9  | Truncated mutation | 1 (ABC)                        |            |
4. Tumour Promoting Roles of TGF-β

TGF-β1 exerts its tumour promoting effects by inducing EMT, migration, invasion, metastasis, angiogenesis and immune suppression [2,9]. High levels of TGF-β1 are commonly detected in many types of solid tumour and positively correlate with disease stage [130–133]. TGF-β1 can be produced by tumour cells or by stromal cells in the tumour microenvironment, including macrophages and platelets [134,135]. As tumours progress, many cancer cells develop genetic abnormalities within the pathway to escape the tumour suppressive effects of TGF-β signalling and, therefore, the excessive production of TGF-β1 drives tumour progression [2,7]. Although it is suggested that the tumour promoting effects of TGF-β1 are mainly mediated through the non-canonical Smad-independent signalling pathway [136–139], there is evidence to show that the canonical Smad-dependent signalling pathway can also be responsible for mediating some of these effects [1–3].

4.1. High Levels of TGF-β in EBV-Associated Cancers

Several early studies showed that TGF-β1 and TGF-β2 were produced by Hodgkin’s Reed-Sternberg (H-RS) cells in vitro and in vivo [140–143]. It was subsequently shown that HL cells produced TGF-β, which contributes to the shift from a Th1-biased towards a Th2-biased T-cell infiltrate characteristics of HL [144]. EBV and its lytic gene product (Zta) have been shown to induce TGF-β1 production and secretion in BL and HeLa cells [145,146]. In patients with NPC, the levels of both the total and active TGF-β1 in serum samples have been reported to be elevated compared to those from healthy individuals with levels positively correlating with disease staging [147]. In support of these observations, our previous study has confirmed that TGF-β1 was up-regulated in EBV-positive NPC tissues compared to non-malignant nasopharyngeal mucosa [148]. There is also evidence to show that EBNA1 and LMP1 induced the expression and secretion of TGF-β1 in epithelial cells in vitro [92,149]. Interestingly, a relatively high intracellular expression of TGF-β1 protein was detected following miR-93-mediated down-regulation of TGFBR2 in NPC cells [108]. In gastric cancer, high levels of TGF-β1 and TGF-β3 expression were detected in tissue samples of gastric carcinoma compared to gastric mucosa, although the status of EBV in these cancer samples examined was unreported [150]. Further, both gastric tissue-derived EBV-infected epithelial cell lines, GT38 and GT39, spontaneously produce biologically active TGF-β1 [75]. These data are consistent with the more recent report that TGF-β1 levels were elevated in EBVaGC [151]. Notably, several mutations on TGF-β1 and TGF-β2 have been detected in EBV-associated cancers (Table 2), pointing to a possible role of EBV in regulating the expression of TGF-β ligands. Further investigations are warranted to examine whether these are gain-of-function mutations that might result in increased levels of TGF-β ligands.

4.2. Contribution of TGF-β Signalling to the Aggressive Phenotypes of EBV-Associated Cancers

Several lines of evidence have shown that TGF-β signalling promotes aggressive phenotypes of EBV-associated epithelial cancers. TGF-β signalling is a major inducer of EMT in cancer cells [152]. EMT is morphologically characterized by changes from an epithelial cell phenotype to a spindle fibroblast-like appearance and functionally characterized by decreased cell adhesion and increase cell migration. Accordingly, TGF-β signalling-associated induction of EMT is considered an important step in the progression of tumour metastasis. Alterations in EMT markers (increased Vimentin and decreased E-cadherin) were detected in clinical NPC samples [153,154], indicating that NPC cells undergo EMT in vivo. Although EBNA1 has been shown to suppress TGF-β-mediated transcription in AdAH and HL cells [95,100], in NPC cells, EBNA1 appeared to up-regulate the expression of TGF-β1 protein leading to a reduction in expression of miR-200a and miR-200b which in turn, up-regulated their target genes ZEB1 and ZEB2, well known mediators of EMT [149]. Recent reports have repeatedly described the underlying mechanisms of the EMT process induced by TGF-β signalling in NPC, and a number of effectors have been identified. There is evidence to demonstrate that components of lipid rafts, flotillin-1 and -2 (Flot1 and Flot2), were highly expressed in primary
NPC tissues [155,156] and that this contributed to the TGF-β1 induction of EMT in NPC. Flot1 was shown to stimulate the expression and secretion of TGF-β1, facilitate the activation of TGF-β/Smad3 signalling to effectuate EMT in NPC cells [155]. Whereas Zhao and colleagues showed that Flot2 was required for TGF-β1-induced EMT in NPC cells through activation of Src [156]. Further, the ability of high-mobility group AT-hook 2 (HMGA2) to induce EMT in NPC cells was attributed to the activation of TGF-β1 signalling pathway [157]. TGF-β1 was also shown to induce EMT in NPC cells by enhancing the expression of formin-like 3 (FMNL3) and Y-box binding protein-1 (YBX1) [153,154]. More recently, it was found that TGF-β1 induced NPC cell growth and migration by down-regulating miRNA-124 which inhibited TGF-β1-mediated responses by targeting the pro-oncogenic lncRNA MALAT1 primarily via the ERK/MAPK pathway [158]. In addition, LMP1-mediated activin/TGF-β signalling through the JNK/SAPK pathway was also involved in the induction of the extracellular matrix protein, fibronectin, a process that may contribute to tumour invasiveness in NPC [92].

In addition to promoting aggressive phenotypes of cancer cells, an emerging role for TGF-β signalling in cancer drug resistance has also been proposed [159,160]. Very recently, it was reported that overexpression of miR-449b in NPC down-regulated TGF-β1, a target gene of TGF-β pathway, leading to increased pro-TGF-β1 activation and cisplatin resistance [161]. The effect of TGF-β in inducing aggressive phenotypes in EBVaGC is currently unexplored and further studies are warranted.

5. Induction of EBV Lytic Reactivation by TGF-β

EBV is able to induce its lytic cycle by switching on the expression of BZLF1 gene which encodes protein Zta [80]. TGF-β was initially shown to induce the viral productive cycle in marmoset B lymphocytes immortalized with EBV [162]. It was subsequently shown that TGF-β induces latent EBV to enter into lytic cycle (as shown by EA expression) in two BL cell lines P3HR-1 and Akata [145,163]. These observations were later confirmed in a series of BL cell lines (Mtu-I, Raji and B95-8) in which TGF-β1 induced BZLF1/Zta expression by an indirect mechanism which required the ERK 1/2 MAPK kinase pathway; Smad signalling alone was not sufficient to mediate TGF-β1 induction of Zta [164]. It was further shown in additional BL cells (Mtu-I, Kem-I and Sav-I) that the PI3K/AKT pathway, acting downstream of ERK 1/2, enabled Smad3 to be acetylated by direct interaction with the co-activator CREB-binding protein to stimulate TGF-β1-induced Zta expression [165]. Different mechanisms of TGF-β1-mediated activation of BZLF1 gene have also been reported. In BL cell lines, Rael and P3HR-1, BZLF1 gene expression appeared to be activated by TGF-β through its mediator Smad proteins [166]. A Smad4-binding element (later termed SBE1) located within the BZLF1 Z promoter (Zp) was identified and both SBE1 and AP-1 motifs were required for TGF-β to activate the expression of BZLF1 through the complex of Smad3/Smad4 associated with the c-Jun/c-Fos proteins of the AP-1 complex [166]. However, this mechanism accounted for only 20–30% of the total TGF-β-mediated activation of transcription from Zp. Subsequently, Iempridee and colleagues identified an additional four SBEs (termed SBE2-5) and showed that TGF-β induced EBV lytic reactivation via the canonical Smad pathway by alleviating ZEB-mediated repression of Zp through multiple SBEs acting in concert [167]. In epithelial cells, TGF-β1 partially induced EBV reactivation in gastric cancer cells GT38 and GT39, as shown by the expression of BZLF1/Zta and early antigen-D, possibly primarily through junB pathway [75]. These studies have collectively demonstrated that TGF-β induces lytic reactivation in latently EBV-infected cells by stimulating the expression of BZLF1 gene/Zta protein through both canonical and non-canonical pathways.

In addition to the BZLF1 Zp, the EBNA1 Qp is also a direct target of the TGF-β signaling pathway. EBNA1 is a DNA-binding protein that binds to the ori-P region of the EBV genome and allows the viral genome to be present as an episome in infected cells [168]. Transcription of the EBNA1 gene in BL and NPC cells is initiated from the Qp [169]. Qp expression is subject to regulation by a number of mechanisms and interestingly, in BL cells, it has been shown that TGF-β transcriptionally repressed EBNA1 Qp through cooperativity of a Smad3/Smad4 complex and the
transcriptional repressor TGIF at the SBE site within Qp [96]. It has also been shown that the Zta protein interfered with JAK/STAT activation of Qp [170] and induced TGF-β production in HeLa cells [146]. Thus, the autocrine/paracrine function of TGF-β is generated by up-regulation of Zta, which then activates the transcription of TGF-β, thereby forming a positive feedback loop to initiate the EBV lytic cycle. In parallel, both TGF-β and Zta repressed Qp to disrupt EBV latency.

6. Concluding Remarks

Since its discovery in 1964, EBV has been implicated in the aetiology of several tumours of both lymphoid and epithelial origin. Although the mechanisms of EBV infection in lymphoid and epithelial cells are different, it is well-recognised that the virus drives cancer development by de-regulating a diverse range of signalling pathways that regulate essential cellular processes [19]. It is perhaps not surprising that EBV acts as a modulator of the TGF-β signalling pathway, a key network that controls various vital processes, such as proliferation, differentiation, apoptosis and migration. Like many other tumours, EBV-associated cancers produce high levels of TGF-β and do not respond to the cytostatic effects of TGF-β, but yet often sustain a functional TGF-β core machinery to promote more aggressive malignant phenotypes. EBV utilises different mechanisms to manipulate the “double-edged sword” nature of TGF-β signalling to fine-tune the TGF-β response at various levels (Figure 2). A balance between latent and lytic infection is crucial for EBV oncogenesis. In latently infected cells, EBV-encoded proteins (EBNA1, LMP1, LMP2A and BARF1) suppress TGF-β-mediated transcription, rendering cells refractory to TGF-β cytostatic effects. When lytic cycle is needed for the spreading of the virus, TGF-β disrupts the latency by stimulating the expression of BZLF1/Zta via both Smad-dependent and Smad-independent pathways which in turn, promotes the production of TGF-β and inhibits the transcription of EBNA1. Intriguingly, it has been shown that the EBV infection rate of epithelial cells can be enhanced by exogenous TGF-β1 and TGF-β1 derived from the epithelial cells facilitated viral transmission by inducing lytic cycle in the donor B-cells in co-culture systems [171,172]. These observations imply that TGF-β signalling might play a critical role in regulating persistent EBV infection, particularly in epithelial cells. Several lines of evidence have shown that the expression of TGFBR2 is down-regulated in NPC and TGF-β/Smad signalling is defective [76,106–108,173] and mutations in SMAD genes have been reported (Table 2). It is currently unclear whether these defects in the canonical pathway would be adequate to result in the loss of BZLF1/Zta expression, thereby facilitate the maintenance of EBV genomes in the nasopharyngeal epithelial cells. This is also relevant to the ability of TGF-β in the induction of differentiation of epithelial cells [174,175]. EBV infection is intimately associated with a number of undifferentiated carcinomas [86], implying that undifferentiated properties of epithelial cells are likely to be a prerequisite for stable EBV latent infection. It has been shown that differentiation of epithelial and B cells triggered EBV lytic reactivation in the latently infected cells [176]. In line with this concept, defects in TGF-β signalling might impair cellular differentiation which results in the suppression of lytic cycle, thereby facilitating latent infection in epithelial cells. Interestingly, it has been shown that in patients with EBVaGC, TGF-β1 levels were significantly associated with the expression of EBV lytic genes in the absence of Helicobacter pylori (H. pylori) infection [151]. These data imply that H. pylori infection prevents EBV lytic induction by suppressing TGF-β1 expression in EBVaGC patients, observations that warrant further investigation.
It will be intriguing to unravel the contribution of EBV infection to the non-canonical Smad TGF-β signalling in NPC [180] and also have data showing that BMP signalling is de-regulated in NPC in vivo [179]. Interestingly, we have previously reported that EBV infection contributed to aberrant S1P signalling in NPC [180] and also have data showing that BMP signalling is de-regulated in NPC in vivo [179]. Interestingly, we have previously reported that EBV infection contributed to aberrant S1P suppressor in DLBCL, to provide a significant proliferative advantage to DLBCL cells in vitro and in suppressing the expression of sphingosine-1-phosphate (S1P) receptor 2 (S1PR2), a bona fide tumour suppressor in DLBCL, to provide a significant proliferative advantage to DLBCL cells in vitro and in vivo [179]. Interestingly, we have previously reported that EBV infection contributed to aberrant S1P signalling in NPC [180] and also have data showing that BMP signalling is de-regulated in NPC (manuscript in preparation). It will be intriguing to unravel the contribution of EBV infection to the non-canonical Smad TGF-β signalling in the development of EBV-associated cancers. A better understanding of these mechanisms may also provide an explanation for the seemingly contradicting roles of EBV-encoded latent proteins in regulating the TGF-β pathway. EBNA1 and LMP1 have been shown to stimulate the expression of BZLF1/Zta via both Smad-dependent and Smad-independent pathways. Zta induces the production of TGF-β1 which in turn, together with Zta, suppress the transcription of EBNA1 from Qp to disrupt EBV latency.

While most of the studies on the TGF-β pathway to date have focused on the roles of canonical Smad2/3/4-dependent signalling, emerging evidence has revealed the contribution of non-canonical Smad1/5/9 signalling dysregulation to lymphomagenesis. In DLBCL, oncogenic miR-155 inhibited Smad5 expression and rendered cells resistant to the growth inhibitory effects of both TGF-β1 and BMPs, via a defective p21 induction and decreased formation of the RB/E2F1 complex [177,178]. More recently, Stelling and colleagues identified TGF-β/TGFR-2/Smad1 axis as the upstream regulator in suppressing the expression of sphingosine-1-phosphate (SIP) receptor 2 (S1PR2), a bona fide tumour suppressor in DLBCL, to provide a significant proliferative advantage to DLBCL cells in vitro and in vivo [179]. Interestingly, we have previously reported that EBV infection contributed to aberrant SIP signalling in NPC [180] and also have data showing that BMP signalling is de-regulated in NPC (manuscript in preparation). It will be intriguing to unravel the contribution of EBV infection to the non-canonical Smad TGF-β signalling in the development of EBV-associated cancers. A better understanding of these mechanisms may also provide an explanation for the seemingly contradicting roles of EBV-encoded latent proteins in regulating the TGF-β pathway. EBNA1 and LMP1 have been shown to stimulate the expression of BZLF1/Zta via both Smad-dependent and Smad-independent pathways. Zta induces the production of TGF-β1 which in turn, together with Zta, suppress the transcription of EBNA1 from Qp to disrupt EBV latency.
treatment with TGFBR1 inhibitors in glioblastoma [183]. This would be an important research area to be explored in EBV-associated cancers, particularly as EBV latent proteins (LMP1 and LMP2A) have been shown to contribute to the induction and maintenance of cancer stem-like cell (CSC) population in NPC [184,185].

Many drugs that target TGF-β signalling have been developed for the treatment of a number of diseases [186]. Some of which have reached clinical trials, including a phase I trial for EBV-positive lymphoma using recombinant cytotoxic-T-lymphocytes with a virus encoding a dominant negative TGFBR2 [187]; however, the results have not been posted for this trial. The main goal of utilising anti-TGF-β therapies in cancer is to reduce excessive levels of TGF-β ligands. However, there are clearly concerns and issues with this approach, such as that TGF-β inhibitors are not cytotoxic and might disrupt the stem cells niche resulting in releasing cancer stem cells from dormancy [186]. TGF-β action is highly context-dependent and influenced by multiple factors, such as interactions with other signalling pathways, disease stage and innate genetic background among individuals. EBV infection is likely to add another level of complexity to anti-TGF-β therapies in EBV-associated cancers. It is also noteworthy that the function of TGF-β signalling in the tumour immune microenvironment (TIME) is important in this regard. TGF-β signalling is a crucial mediator not only of changes to the tumour cell phenotype but also of changes in the stromal environment [7]. This is particularly relevant to the development of EBV-based immunotherapies. It has recently been shown that a transcriptional signature of TGF-β pathway activation was associated with low levels of stromal tumour-infiltrating lymphocytes (TILs) and poor prognosis in NPC patients [188]. The TIME in both NPC and HL may influence the response to immunotherapeutic interventions and it might be important to determine the level of TGF-β expression in these tumours as a prognostic indicator of response to such therapies. Therefore, a more complete understanding of the multifaceted function of TGF-β signalling in EBV-associated cancers is required to determine if this pathway can be manipulated therapeutically for the management of patients with these diseases.

**Funding:** This work was supported by Newton-Ungku Omar Fund MR/P013201/1 (IF016-2017) from the Academy of Sciences Malaysia and Medical Research Council UK, Fundamental Research Grant Scheme (FP013-2016) from the Ministry of Higher Education Malaysia and High Impact Research Grant UM.C/625/1/HIR/MOHE/DENT/23 from the University of Malaya. The APC was funded by Newton-Ungku Omar Fund MR/P013201/1 (IF016-2017) and Institute of Research Management & Service (IPPP), University of Malaya.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Derynck, R.; Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. *Nature* 2003, 425, 577–584. [CrossRef] [PubMed]
2. Siegel, P.M.; Massague, J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. *Nat. Rev. Cancer* 2003, 3, 807–821. [CrossRef] [PubMed]
3. Derynck, R.; Akhurst, R.J.; Balmain, A. TGF-β signaling in tumor suppression and cancer progression. *Nat. Genet.* 2001, 29, 117–129. [CrossRef] [PubMed]
4. Takehara, K.; LeRoy, E.C.; Grotendorst, G.R. TGF-β inhibition of endothelial cell proliferation: Alteration of EGF binding and EGF-induced growth-regulatory (competence) gene expression. *Cell* 1987, 49, 415–422. [CrossRef]
5. Moses, H.L.; Coffey, R.J., Jr.; Leof, E.B.; Lyons, R.M.; Keski-Oja, J. Transforming growth factor beta regulation of cell proliferation. *J. Cell. Physiol. Suppl.* 1987, (Suppl. 5), 1–7. [CrossRef]
6. Stoeck, M.; Howe, R.C.; Miescher, S.; von Fliedner, V.; MacDonald, H.R. Effect of transforming growth factor beta on the EL4 thymoma variant EL4/6:1. Dissociation of inhibition of proliferation from expression of IL-1 and IL-2 receptors. *Immunobiology* 1990, 181, 13–21. [CrossRef]
7. Pickup, M.; Novitskiy, S.; Moses, H.L. The roles of TGF-β in the tumour microenvironment. *Nat. Rev. Cancer* 2013, 13, 788–799. [CrossRef] [PubMed]
8. Yanagihara, K.; Tsumuraya, M. Transforming growth factor beta 1 induces apoptotic cell death in cultured human gastric carcinoma cells. *Cancer Res.* 1992, 52, 4042–4045. [PubMed]

9. Lebrun, J.J. The Dual Role of TGF-β in Human Cancer: From Tumor Suppression to Cancer Metastasis. *ISRN Mol. Biol.* 2012, 2012, 381–428. [CrossRef] [PubMed]

10. Oft, M.; Heider, K.H.; Beug, H. TGF-β signaling is necessary for carcinoma cell invasiveness and metastasis. *Curr. Biol.* 1998, 8, 1243–1252. [CrossRef]

11. Ueki, N.; Nakazato, M.; Ohkawa, T.; Ikeda, T.; Amuro, Y.; Hada, T.; Higashino, K. Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth. *Biochim. Biophys. Acta* 1992, 1137, 189–196. [CrossRef]

12. Torre-Amione, G.; Beauchamp, R.D.; Koeppen, H.; Park, B.H.; Schreiber, H.; Moses, H.L.; Rowley, D.A. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. *Proc. Natl. Acad. Sci. USA* 1990, 87, 1486–1490. [CrossRef] [PubMed]

13. McEarchern, J.A.; Kobie, J.J.; Mack, V.; Wu, R.S.; Meade-Tollin, L.; Arteaga, C.L.; Dumont, N.; Besselsen, D.; Seftor, E.; Hendrix, M.J.; et al. Invasion and metastasis of a mammary tumor involves TGF-β signaling. *Int. J. Cancer* 2001, 91, 76–82. [CrossRef]

14. Lehmann, K.; Janda, E.; Pierreux, C.E.; Rytoma, M.; Schulze, A.; McMahon, M.; Hill, C.S.; Beug, H.; Downward, J. Raf induces TGF-β production while blocking its apoptotic but not invasive responses: A mechanism leading to increased malignancy in epithelial cells. *Genes Dev.* 2000, 14, 2610–2622. [CrossRef] [PubMed]

15. Zhang, Y.Y.; Li, X.; Sui, L.H.; Wang, Q.; Li, P.; Fu, S.B. Functional study on TGF-β/Smads signaling pathway in human ovarian cancer cells. *Yi Chuan Xue Bao* 2004, 31, 759–765. [PubMed]

16. Chen, C.R.; Kang, Y.; Massague, J. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. *Proc. Natl. Acad. Sci. USA.* 2001, 98, 992–999. [CrossRef] [PubMed]

17. Mirzaii, H.; Faghihloo, E. Viruses as key modulators of the TGF-β pathway; a double-edged sword involved in cancer. *Rev. Med. Virol.* 2018, 28. [CrossRef] [PubMed]

18. Epstein, M.A.; Achong, B.G.; Barr, Y.M. Virus Particles in Cultured Lymphoblasts from Burkitt’s Lymphoma. *Lancet* 1964, 1, 702–703. [CrossRef]

19. Young, L.S.; Yap, L.F.; Murray, P.G. Epstein-Barr virus: More than 50 years old and still providing surprises. *Nat. Rev. Cancer* 2016, 16, 789–802. [CrossRef] [PubMed]

20. Assoian, R.K.; Komoriya, A.; Meyers, C.A.; Miller, D.M.; Sporn, M.B. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. *J. Biol. Chem.* 1983, 258, 7155–7160. [PubMed]

21. Childs, C.B.; Proper, J.A.; Tucker, R.F.; Moses, H.L. Serum contains a platelet-derived transforming growth factor. *Proc. Natl. Acad. Sci. USA* 1982, 79, 5312–5316. [CrossRef] [PubMed]

22. Derynck, R.; Lindquist, P.B.; Lee, A.; Wen, D.; Tamm, J.; Graycar, J.L.; Rhee, L.; Mason, A.J.; Miller, D.A.; Coffey, R.J.; et al. A new type of transforming growth factor-beta, TGF-β3. *EMBO J.* 1988, 7, 3737–3743. [PubMed]

23. Segarini, P.R.; Roberts, A.B.; Rosen, D.M.; Sedyin, S.M. Membrane binding characteristics of two forms of transforming growth factor-beta. *J. Biol. Chem.* 1987, 262, 14655–14662. [PubMed]

24. Sporn, M.B.; Roberts, A.B.; Wakefield, L.M.; Assoian, R.K. Transforming growth factor-beta: Biological function and chemical structure. *Science* 1986, 233, 532–534. [CrossRef] [PubMed]

25. Derynck, R.; Jarrett, J.A.; Chen, E.Y.; Eaton, D.H.; Bell, J.R.; Assoian, R.K.; Roberts, A.B.; Sporn, M.B.; Goeddel, D.V. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. *Nature* 1985, 316, 701–705. [CrossRef] [PubMed]

26. Gentry, L.E.; Lioubin, M.N.; Purchio, A.F.; Marquardt, H. Molecular events in the process of recombinant type 1 pre-pro-transforming growth factor beta to the mature polypeptide. *Mol. Cell. Biol.* 1988, 8, 4162–4168. [CrossRef] [PubMed]

27. Dubois, C.M.; Laprise, M.H.; Blanchette, F.; Gentry, L.E.; Leduc, R. Processing of transforming growth factor beta 1 precursor by human furin convertase. *J. Biol. Chem.* 1995, 270, 10618–10624. [CrossRef] [PubMed]
28. Gentry, L.E.; Nash, B.W. The pro domain of pre-pro-transforming growth factor beta 1 when independently expressed is a functional binding protein for the mature growth factor. *Biochemistry* 1990, 29, 6851–6857. [CrossRef] [PubMed]

29. Barcellos-Hoff, M.H.; Derynck, R.; Tsang, M.L.; Weatherbee, J.A. Transforming growth factor-beta activation in irradiated murine mammary gland. *J. Clin. Investig.* 1994, 93, 892–899. [CrossRef] [PubMed]

30. Jullien, P.; Berg, T.M.; Lawrence, D.A. Acidic cellular environments: Activation of latent TGF-β and sensitization of cellular responses to TGF-beta and EGF. *Int. J. Cancer* 1989, 43, 886–891. [CrossRef] [PubMed]

31. Khalil, N. TGF-β: From latent to active. *Microbes Infect* 1999, 1, 1255–1263. [CrossRef]

32. Lin, H.Y.; Wang, X.F.; Ng-Eaton, E.; Weinberg, R.A.; Lodish, H.F. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. *Cell* 1992, 68, 775–785. [CrossRef]

33. Ebner, R.; Chen, R.H.; Shum, L.; Lawler, S.; Zioncheck, T.F.; Lee, A.; Lopez, A.R.; Derynck, R. Cloning of a type I TGF-β receptor and its effect on TGF-β binding to the type II receptor. *Science* 1993, 260, 1344–1348. [CrossRef] [PubMed]

34. Zhang, Y.; Feng, X.; We, R.; Derynck, R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. *Nature* 1996, 383, 168–172. [CrossRef] [PubMed]

35. Sekelsky, J.J.; Newfeld, S.J.; Raftery, L.A.; Chartoff, E.H.; Gelbart, W.M. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. *Genetics* 1995, 139, 1347–1358. [PubMed]

36. Raftery, L.A.; Twombly, V.; Wharton, K.; Gelbart, W.M. Genetic screens to identify elements of the decapentaplegic signaling pathway in Drosophila. *Genetics* 1995, 139, 241–254. [PubMed]

37. Moustakas, A.; Souchelnytskyi, S.; Heldin, C.H. Smad regulation in TGF-β signal transduction. *J. Cell Sci.* 2001, 114, 4359–4369. [PubMed]

38. Savage, C.; Das, P.; Finelli, A.L.; Townsend, S.R.; Sun, C.Y.; Baird, S.E.; Padgett, R.W. Caenorhabditis elegans components. *Proc. Natl. Acad. Sci. USA* 1996, 93, 790–794. [CrossRef] [PubMed]

39. Wu, G.; Chen, Y.G.; Ozdamar, B.; Gyuricza, C.A.; Chong, P.A.; Wrana, J.L.; Massague, J.; Shi, Y. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. *Science* 1997, 275, 465–471. [CrossRef] [PubMed]

40. Wu, G.; Chen, Y.G.; Ozdamar, B.; Gyuricza, C.A.; Chong, P.A.; Wrana, J.L.; Massague, J.; Shi, Y. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. *Science* 1997, 275, 465–471. [CrossRef] [PubMed]

41. Tsukazaki, T.; Chiang, T.A.; Davison, A.F.; Attisano, L.; Wrana, J.L. SARA, a FYVE domain protein that recruits Smad2 to the TGF-β receptor. *Cell* 1998, 95, 779–791. [CrossRef]

42. Wu, J.W.; Hu, M.; Chai, J.; Seoane, J.; Huse, M.; Li, C.; Rigotti, D.J.; Kyin, S.; Mui, T.W.; Fairman, R.; et al. Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad signaling in TGF-β signaling. *Mol. Cell* 2001, 8, 1277–1289. [CrossRef]

43. Chacko, B.M.; Qin, B.Y.; Tiwari, A.; Shi, G.; Lam, S.; Hayward, L.J.; De Caestecker, M.; Lin, K. Structural basis of heteromeric smad protein assembly in TGF-β signaling. *Mol. Cell* 2004, 15, 813–823. [CrossRef] [PubMed]

44. Nakao, A.; Imamura, T.; Souchelnytskyi, S.; Kawabata, M.; Ishitaki, A.; Oda, E.; Tamaki, K.; Hanai, J.; Heldin, C.H.; Miyazono, K.; et al. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. *EMBO J.* 1997, 16, 5353–5362. [CrossRef] [PubMed]

45. Topper, J.N.; DiChiara, M.R.; Brown, J.D.; Williams, A.J.; Falb, D.; Collins, T.; Gimbrone, M.A., Jr. CREB binding protein is a required coactivator for Smad-dependent, transforming growth factor beta transcriptional responses in endothelial cells. *Proc. Natl. Acad. Sci. USA* 1998, 95, 9506–9511. [CrossRef] [PubMed]

46. Seoane, J.; Le, H.V.; Shen, L.; Anderson, S.A.; Massague, J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. *Cell* 2004, 117, 211–223. [CrossRef]

47. Yamamura, Y.; Hua, X.; Bergelson, S.; Lodish, H.F. Critical role of Smads and AP-1 complex in transforming growth factor-beta -dependent apoptosis. *J. Biol. Chem.* 2000, 275, 36295–36302. [CrossRef] [PubMed]

48. Hanyu, A.; Ishidou, Y.; Ebisawa, T.; Shimanuki, T.; Imamura, T.; Miyazono, K. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling. *J. Cell Biol.* 2001, 155, 1017–1027. [CrossRef] [PubMed]

49. Yan, X.; Liu, Z.; Chen, Y. Regulation of TGF-β signaling by Smad7. *Acta Biochim. Biophys. Sin.* 2009, 41, 263–272. [CrossRef] [PubMed]
50. Kavsak, P.; Rasmussen, R.K.; Causing, C.G.; Bonni, S.; Zhu, H.; Thomsen, G.H.; Wrana, J.L. Smad7 binds to Smurfl2 to form an E3 ubiquitin ligase that targets the TGF-β receptor for degradation. *Mol. Cell* 2000, 6, 1365–1375. [CrossRef]

51. Ebisawa, T.; Fukuchi, M.; Murakami, G.; Chiba, T.; Tanaka, K.; Imamura, T.; Miyazono, K. Smurfl interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. *J. Biol. Chem.* 2001, 276, 12477–12480. [CrossRef] [PubMed]

52. Hayashi, H.; Abdollah, S.; Qiu, Y.; Cai, J.; Xu, Y.Y.; Grinnell, B.W.; Richardson, M.A.; Topper, J.N.; Gimbrone, M.A., Jr.; Wrana, J.L.; et al. The MAD-related protein Smad7 associates with the TGF-β receptor and functions as an antagonist of TGF-β signaling. *Cell* 1997, 89, 1165–1173. [CrossRef]

53. Zhang, S.; Fei, T.; Zhang, L.; Zhang, R.; Chen, F.; Ning, Y.; Han, Y.; Feng, X.H.; Meng, A.; Chen, Y.G. Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation. *Mol. Cell. Biol.* 2007, 27, 4488–4499. [CrossRef] [PubMed]

54. Yan, X.; Liao, H.; Cheng, M.; Shi, X.; Lin, X.; Feng, X.H.; Chen, Y.G. Smad7 Protein Interacts with Receptor-regulated Smads (R-Smads) to Inhibit Transforming Growth Factor-beta (TGF-β)/Smad Signaling. *J. Biol. Chem.* 2016, 291, 382–392. [CrossRef] [PubMed]

55. Galliher, A.J.; Schiemann, W.P. Src phosphorylates Tyr284 in TGF-β type II receptor and regulates TGF-β stimulation of p38 MAPK during breast cancer cell proliferation and invasion. *Cancer Res.* 2007, 67, 3752–3758. [CrossRef] [PubMed]

56. Lee, M.K.; Pardoux, C.; Hall, M.C.; Lee, P.S.; Warburton, D.; Qing, J.; Smith, S.M.; Derynck, R. TGF-β activates Smad-dependent transcription through SUMO-1 modification of Smad4. *J. Biol. Chem.* 2003, 278, 50833–50842. [CrossRef] [PubMed]

57. Lee, M.K.; Pardoux, C.; Hall, M.C.; Lee, P.S.; Warburton, D.; Qing, J.; Smith, S.M.; Derynck, R. TGF-β activates Erk MAP kinase signalling through direct phosphorylation of ShcA. *EMBO J.* 2007, 26, 3957–3967. [CrossRef] [PubMed]

58. Ya, J.Y.; Shin, I.; Arteaga, C.L. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. *J. Biol. Chem.* 2005, 280, 10870–10876. [CrossRef] [PubMed]

59. Ohshima, T.; Shimotohno, K. Transforming growth factor-beta-mediated signaling via the p38 MAP kinase pathway activates Smad-dependent transcription through SUMO-1 modification of Smad4. *Mol. Cell. Biol.* 2007, 27, 12477–12480. [CrossRef] [PubMed]

60. Reynisdottir, I.; Polyak, K.; Iavarone, A.; Massague, J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. *Genes Dev.* 1995, 9, 1831–1845. [CrossRef] [PubMed]

61. Laiho, M.; DeCaprio, J.A.; Ludlow, J.W.; Livingston, D.M.; Massague, J. Growth inhibition by TGF-β stimulates p21(Cip1) and p27(Kip1) in human breast carcinoma cells in vivo. *Clin. Lymphoma Myeloma Leuk.* 2012, 12, 138–143. [CrossRef] [PubMed]

62. Warner, B.J.; Blain, S.W.; Seoane, J.; Massague, J. Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G1(1) arrest pathway. *Mol. Cell. Biol.* 1999, 19, 5913–5922. [CrossRef] [PubMed]

63. Bakhshayesh, M.; Zaker, F.; Hashemi, M.; Katebi, M.; Solaimani, M. TGF-β1-mediated apoptosis associated with SMAD-dependent mitochondrial Bcl-2 expression. *Clin. Lymphoma Myeloma Leuk.* 2012, 12, 138–143. [CrossRef] [PubMed]

64. Yang, W.; Shen, J.; Wu, M.; Arsura, M.; FitzGerald, M.; Suldan, Z.; Kim, D.W.; Hofmann, C.S.; Pianetti, S.; Romieu-Mourez, R.; et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. *Oncogene* 2001, 20, 1688–1702. [CrossRef] [PubMed]

65. Claassen, G.F.; Hann, S.R. A role for transcriptional repression of p21Cip1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. *Proc. Natl. Acad. Sci. USA* 2000, 97, 9498–9503. [CrossRef] [PubMed]

66. Wang, B.; Blain, S.W.; Seoane, J.; Massague, J. Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G1(1) arrest pathway. *Mol. Cell. Biol.* 1999, 19, 5913–5922. [CrossRef] [PubMed]
69. MacDonald, I.; Wang, H.; Grand, R.; Armitage, R.J.; Fanslow, W.C.; Gregory, C.D.; Gordon, J. Transforming growth factor-beta 1 cooperates with anti-immunoglobulin for the induction of apoptosis in group I (biopsy-like) Burkitt lymphoma cell lines. Blood 1996, 87, 1147–1154. [PubMed]

70. Saltzman, A.; Munro, R.; Seafoord, G.; Franks, C.; Jaye, M.; Ivashchenko, Y. Transforming growth factor-beta-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp. Cell Res. 1998, 242, 244–254. [CrossRef] [PubMed]

71. Inman, G.J.; Allday, M.J. Apoptosis induced by TGF-β 1 in Burkitt’s lymphoma cells is caspase 8 dependent but is death receptor independent. J. Immunol. 2000, 165, 2500–2510. [CrossRef] [PubMed]

72. Blomhoff, H.K.; Smeland, E.; Mustafa, A.S.; Godal, T.; Ohlsson, R. Epstein-Barr virus mediates a switch in responsiveness to transforming growth factor, type beta, in cells of the B cell lineage. Eur. J. Immunol. 1987, 17, 299–301. [CrossRef] [PubMed]

73. Arvanitakis, L.; Yaseen, N.; Sharma, S. Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-β1-mediated growth inhibition in EBV-positive B cells. J. Immunol. 1995, 155, 1047–1056. [PubMed]

74. Kumar, A.; Rogers, T.; Maizel, A.; Sharma, S. Loss of transforming growth factor beta 1 receptors and its effects on the growth of EBV-transformed human B cells. J. Immunol. 1991, 147, 998–1006. [PubMed]

75. Fukuda, M.; Ikuta, K.; Yanagihara, K.; Tajima, M.; Kuratsune, H.; Kurata, T.; Sairenji, T. Effect of transforming growth factor-β1 on the cell growth and Epstein-Barr virus reactivation in EBV-infected epithelial cell lines. Virology 2001, 288, 109–118. [CrossRef] [PubMed]

76. Xiao, J.; Xiang, Q.; Xiao, Y.C.; Su, Z.J.; Huang, Z.F.; Zhang, Q.H.; Tan, Y.; Li, X.K.; Huang, Y.D. The effect of transforming growth factor-beta 1 on nasopharyngeal carcinoma cells: Inensitive to cell growth but functional to TGF-β/Smad pathway. J. Exp. Clin. Cancer Res. 2010, 29, 35. [CrossRef] [PubMed]

77. Gu, S.; Tann, B.; Zeng, Y.; Zhou, W.; Li, K.; Zhao, M. Establishment of an epithelial cell line (CNE-2) from a NPC patient with poorly differentiated squamous cell carcinoma. Chin. J. Cancer 1983, 2, 70.

78. Takanashi, M.; Li, J.; Shirakata, M.; Mori, S.; Hirai, K. Tumorigenicity of mouse BALB/c 3T3 fibroblast cells which express Epstein-Barr virus-encoded LMP1 and show normal growth phenotypes in vitro is correlated with loss of transforming growth factor-β1-mediated growth inhibition. Arch. Virol. 1999, 144, 241–257. [CrossRef] [PubMed]

79. Tsurumi, T.; Fujita, M.; Kudoh, A. Latent and lytic Epstein-Barr virus replication strategies. Rev. Med. Virol. 2005, 15, 3–15. [CrossRef] [PubMed]

80. Countryman, J.; Miller, G. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. USA 1985, 82, 4085–4089. [CrossRef] [PubMed]

81. Countryman, J.; Gradoville, L.; Bhaduri-McIntosh, S.; Ye, J.; Heston, L.; Himmelfarb, S.; Shed, D.; Miller, G. Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus. J. Virol. 2009, 83, 10694–10709. [CrossRef] [PubMed]

82. Bhende, P.M.; Dickerson, S.J.; Sun, X.; Feng, W.H.; Kenney, S.C. X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J. Virol. 2007, 81, 7363–7370. [CrossRef] [PubMed]

83. Sun, C.C.; Thorley-Lawson, D.A. Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J. Virol. 2007, 81, 13566–13577. [CrossRef] [PubMed]

84. Temple, R.M.; Zhu, J.; Budgeon, L.; Christensen, N.D.; Meyers, C.; Sample, C.E. Efficient replication of Epstein-Barr virus in stratified epithelium in vitro. Proc. Natl. Acad. Sci. USA 2014, 111, 16544–16549. [CrossRef] [PubMed]

85. Rickinson, A.B. Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin. Cancer Biol. 2014, 29, 99–115. [CrossRef] [PubMed]

86. Yap, L.F.; Lo, K.W. Epstein-Barr virus and epithelial carcinogenesis. In DNA Tumour Viruses: Virology, Pathogenesis and Vaccines; Roberts, I.S., Ed.; Caister Academic Press: Poole, UK, 2018; pp. 139–161. ISBN 978-1-910190-80-7.

87. Kenney, J.L.; Guinness, M.E.; Reiss, M.; Lacy, J. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents. Int. J. Cancer 2001, 91, 89–98. [CrossRef]
88. Inman, G.J.; Allday, M.J. Resistance to TGF-β1 correlates with a reduction of TGF-β type II receptor expression in Burkitt’s lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines. J. Gen. Virol. 2000, 81, 1567–1578. [CrossRef] [PubMed]

89. Prokova, V.; Mosialos, G.; Kardassis, D. Inhibition of transforming growth factor beta signaling and Smad-dependent activation of transcription by the Latent Membrane Protein 1 of Epstein-Barr virus. J. Biol. Chem. 2002, 277, 9342–9350. [CrossRef] [PubMed]

90. Mori, N.; Morishita, M.; Tsukazaki, T.; Yamamoto, N. Repression of Smad-dependent transforming growth factor-beta signaling by Epstein-Barr virus latent membrane protein 1 through nuclear factor-κB. Int. J. Cancer 2003, 105, 661–668. [CrossRef] [PubMed]

91. Liu, Q.; Guan, X.; Lv, J.; Li, X.; Wang, Y.; Li, L. Limb-bud and Heart (LBH) functions as a tumor suppressor of 662 2018. [CrossRef] [PubMed]

92. Morris, M.A.; Dawson, C.W.; Laverick, L.; Davis, A.M.; Dudman, J.P.; Raveenthiraraj, S.; Ahmad, Z.; Yap, L.-E.; Young, L.S. The Epstein-Barr virus encoded LMP1 oncoprotein modulates cell adhesion via regulation of activin A/TGFβ and β1 integrin signalling. Sci. Rep. 2016, 6, 20033. [CrossRef] [PubMed]

93. Li, Q.; Guan, X.; Lv, J.; Li, X.; Wang, Y.; Li, L. Limb-bud and Heart (LBH) functions as a tumor suppressor of 662 2018. [CrossRef] [PubMed]

94. Fukuda, M.; Longnecker, R. Latent membrane protein 2A inhibits transforming growth factor-β-mediated growth inhibition. Mol. Cancer 2010, 9, 155. [CrossRef] [PubMed]

95. Wood, V.H.; O’Neil, J.D.; Wei, W.; Stewart, S.E.; Dawson, C.W.; Young, L.S. Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGF-β signaling pathways. Oncogene 2007, 26, 4135–4147. [CrossRef] [PubMed]

96. Liang, C.L.; Tsai, C.N.; Chung, P.J.; Chen, J.L.; Sun, C.M.; Chen, R.H.; Hong, J.H.; Chang, Y.S. Transcription of Epstein-Barr virus-encoded nuclear antigen 1 promoter Qp is repressed by transforming growth factor-beta via Smad4 binding element in human BL cells. Virology 2000, 277, 184–192. [CrossRef] [PubMed]

97. Foote, L.C.; Marshak-Rothstein, A.; Rothstein, T.L. Tolerant B lymphocytes acquire resistance to Fas-mediated apoptosis after treatment with interleukin 4 but not after treatment with specific antigen unless a surface immunoglobulin threshold is exceeded. J. Exp. Med. 1998, 187, 847–853. [CrossRef] [PubMed]

98. Holder, M.J.; Knox, K.; Gordon, J. Factors modifying survival pathways of germinal center B cells. Glucocorticoids and transforming growth factor-beta, but not cyclosporin A or anti-CD19, block surface immunoglobulin-mediated rescue from apoptosis. Eur. J. Immunol. 1992, 22, 2725–2728. [CrossRef] [PubMed]

99. Sater, R.A.; Sandel, P.C.; Monroe, J.G. B cell receptor-induced apoptosis in primary transitional murine B cells: signaling requirements and modulation by T cell help. Int. Immunol. 1998, 10, 1673–1682. [CrossRef] [PubMed]

100. Flavell, J.R.; Baumforth, K.R.; Wood, V.H.; Davies, G.L.; Wei, W.; Reynolds, G.M.; Morgan, S.; Boyce, A.; Kelly, G.L.; Young, L.S.; et al. Down-regulation of the TGF-β-target gene, PTEN, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood 2008, 111, 292–301. [CrossRef] [PubMed]

101. Hornadasch, M.; Raschke, E.E.; Bommer, G.; Schuhmacher, M.; Dumont, E.; Kuklik-Roos, C.; Eick, D.; Kempkes, B. Epstein-Barr virus antagonizes the antiproliferative activity of transforming growth factor-beta but does not abolish its signaling. Int. J. Cancer 2002, 101, 442–447. [CrossRef] [PubMed]

102. Campion, E.M.; Hakimjavadi, R.; Loughran, S.T.; Phelan, S.; Smith, S.M.; D’Souza, B.N.; Tierney, R.J.; Bell, A.I.; Cahill, P.A.; Walls, D. Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor beta1-induced B-cell apoptosis. J. Virol. 2014, 88, 5001–5013. [CrossRef] [PubMed]

103. Kim, D.H.; Chang, M.S.; Yoon, C.J.; Middeldorp, J.M.; Martinez, O.M.; Byeon, S.J.; Rha, S.Y.; Kim, S.H.; Kim, Y.S.; Woo, J.H. Epstein-Barr virus BARF1-induced NfkappaB/miR-146a/SMAD4 alterations in stomach cancer cells. Oncotarget 2016, 7, 82213–82227. [CrossRef] [PubMed]

104. Fukuda, M.; Kurosaki, H.; Sairenji, T. Loss of functional transforming growth factor (TGF)-beta type II receptor results in insensitivity to TGF-beta1-mediated apoptosis and Epstein-Barr virus reactivation. J. Med. Virol. 2006, 78, 1456–1464. [CrossRef] [PubMed]

105. Mao, S.; Yang, W.; Ai, L.; Li, Z.; Jin, J. Transforming growth factor beta type II receptor as a marker in diffuse large B cell lymphoma. Tumour Biol. 2015, 36, 9903–9908. [CrossRef] [PubMed]
106. Fang, W.; Li, X.; Jiang, Q.; Liu, Z.; Yang, H.; Wang, S.; Xie, S.; Liu, Q.; Liu, T.; Huang, J.; et al. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. *J. Transl. Med.* 2008, 6, 32. [CrossRef] [PubMed]

107. Zhang, W.; Zeng, Z.; Fan, S.; Wang, J.; Yang, J.; Zhou, Y.; Li, X.; Huang, D.; Liang, F.; Wu, M.; et al. Evaluation of the prognostic value of TGF-beta superfamily type I receptor and TGF-beta type II receptor expression in nasopharyngeal carcinoma using high-throughput tissue microarrays. *J. Mol. Histol.* 2008, 43, 297–306. [CrossRef] [PubMed]

108. Lyu, X.; Fang, W.; Cai, L.; Zheng, H.; Ye, Y.; Zhang, L.; Li, J.; Peng, H.; Cho, W.C.; Wang, E.; et al. TGFbetaR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness. *Mol. Cancer* 2014, 13, 51. [CrossRef] [PubMed]

109. Ma, F.; Wang, Z.; Wang, J.; Hu, C. MicroRNA-19a promotes nasopharyngeal carcinoma by targeting transforming growth factor beta receptor 2. *Exp. Ther. Med.* 2017, 14, 1419–1426. [CrossRef] [PubMed]

110. Ma, J.; Xuan, S.H.; Li, Y.; Zhang, Z.P.; Li, X.H. Role of the TGFbeta/PDCD4/AP-1 Signaling Pathway in Nasopharyngeal Carcinoma and Its Relationship to Prognosis. *Cell. Physiol. Biochem.* 2017, 43, 1392–1401. [CrossRef] [PubMed]

111. Paterson, I.C.; Matthews, J.B.; Huntley, S.; Robinson, C.M.; Fahey, M.; Parkinson, E.K.; Prime, S.S. Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma. *J. Pathol.* 2001, 193, 458–467. [CrossRef]

112. Chan, A.S.; To, K.F.; Lo, K.W.; Mak, K.F.; Pak, W.; Chiu, B.; Tse, G.M.; Ding, M.; Li, X.; Lee, J.C.; et al. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. *Cancer Res.* 2000, 60, 5365–5370. [PubMed]

113. Lo, K.W.; Teo, P.M.; Hui, A.B.; To, K.F.; Tsang, Y.S.; Chan, S.Y.; Mak, K.F.; Lee, J.C.; Huang, D.P. High resolution allelotype of microdissected primary nasopharyngeal carcinoma. *Cancer Res.* 2000, 60, 3348–3353. [PubMed]

114. Chen, H.C.; Chen, G.H.; Chen, Y.H.; Liao, W.L.; Liu, C.Y.; Chang, K.P.; Chang, Y.S.; Chen, S.J. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. *Br. J. Cancer* 2009, 100, 1002–1011. [CrossRef] [PubMed]

115. Wan, X.X.; Yi, H.; Qu, J.Q.; He, Q.Y.; Xiao, Z.Q. Integrated analysis of the differential cellular and EBV miRNA expression profiles in microdissected nasopharyngeal carcinoma and non-cancerous nasopharyngeal tissues. *Oncol. Rep.* 2015, 34, 2585–2601. [CrossRef] [PubMed]

116. Xu, Y.F.; Li, Y.Q.; Guo, R.; He, Q.M.; Ren, X.Y.; Tang, X.R.; Jia, W.H.; Kang, T.B.; Zeng, M.S.; Sun, Y.; et al. Identification of miR-143 as a tumour suppressor in nasopharyngeal carcinoma based on microRNA expression profiling. *Int. J. Biochem. Cell Biol.* 2015, 61, 120–128. [CrossRef] [PubMed]

117. Deng, C.; Lin, Y.X.; Qi, X.K.; He, G.P.; Zhang, Y.; Zhang, H.J.; Xu, M.; Feng, Q.S.; Bei, J.X.; Zeng, Y.X.; et al. TNFRSF19 inhibits TGFbeta signaling through interaction with TGFbeta receptor type I to promote tumorigenesis. *Cancer Res.* 2018. [CrossRef] [PubMed]

118. Lin, D.C.; Meng, X.; Hazawa, M.; Nagata, Y.; Varela, A.M.; Xu, L.; Sato, Y.; Liu, L.Z.; Ding, L.W.; Sharma, A.; et al. The genomic landscape of nasopharyngeal carcinoma. *Nat. Genet.* 2014, 46, 866–871. [CrossRef] [PubMed]

119. Zheng, H.; Dai, W.; Cheung, A.K.; Ko, J.M.; Kan, R.; Wong, B.W.; Leong, M.M.; Deng, M.; Kwok, T.C.; Chan, J.Y.; et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-kappaB pathway regulators in nasopharyngeal carcinoma. *Proc. Natl. Acad. Sci. USA* 2016, 113, 11283–11288. [CrossRef] [PubMed]

120. Li, Y.Y.; Chung, G.T.; Lui, V.W.; To, K.F.; Ma, B.B.; Chow, C.; Woo, J.K.; Yip, K.Y.; See, J.; Hui, E.P.; et al. Exome and genome sequencing of nasopharynx cancer identifies NF-kappaB pathway activating mutations. *Nat. Commun.* 2017, 8, 14121. [CrossRef] [PubMed]

121. Liang, Q.; Yao, X.; Tang, S.; Zhang, J.; Yau, T.O.; Li, X.; Tang, C.M.; Kang, W.; Lung, R.W.; Li, J.W.; et al. Integrative identification of Epstein-Barr virus-associated mutations and epigenetic alterations in gastric cancer. *Gastroenterology* 2014, 147, 1350–1362. [CrossRef] [PubMed]

122. Boger, C.; Kruger, S.; Behrens, H.M.; Bock, S.; Haag, J.; Kalthoff, H.; Rocken, C. Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations. *Ann. Oncol.* 2017, 28, 1005–1014. [CrossRef] [PubMed]
123. Liu, Y.; Abdul Razak, F.R.; Terpstra, M.; Chan, F.C.; Saber, A.; Nijland, M.; van Imhoff, G.; Visser, L.; Gascoyne, R.; Steidl, C.; et al. The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing. *Leukemia* 2014, 28, 2248–2251. [CrossRef] [PubMed]

124. Hudnall, S.D.; Meng, H.; Lozovatsky, L.; Li, P.; Strout, M.; Kleinstein, S.H. Recurrent genetic defects in classical Hodgkin lymphoma cell lines. *Leuk. Lymphoma* 2016, 57, 2890–2900. [CrossRef] [PubMed]

125. Zhang, J.; Grubar, V.; Love, C.L.; Banerjee, A.; Richards, K.L.; Mieczkowski, P.A.; Dunphy, C.; Choi, W.; Au, W.Y.; Srivastava, G.; et al. Genetic heterogeneity of diffuse large B-cell lymphoma. *Proc. Natl. Acad. Sci. USA* 2013, 110, 1398–1403. [CrossRef] [PubMed]

126. Novak, A.J.; Asmann, Y.W.; Maurer, M.J.; Wang, C.; Slager, S.L.; Hodge, L.S.; Manske, M.; Price-Troska, T.; Yang, Z.Z.; Zimmermann, M.T.; et al. Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunotherapy-treated diffuse large B-cell lymphoma. *Blood Cancer J.* 2015, 5, e346. [CrossRef] [PubMed]

127. Park, H.Y.; Lee, S.B.; Yoo, H.Y.; Kim, S.J.; Kim, W.S.; Kim, J.I.; Ko, Y.H. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma. *Oncotarget* 2016, 7, 86433–86445. [CrossRef] [PubMed]

128. Greenawalt, D.M.; Liang, W.S.; Saif, S.; Johnson, J.; Todorov, P.; Dulak, A.; Enriquez, D.; Halperin, R.; Ahmed, A.; Saveliev, V.; et al. Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum. *Oncotarget* 2017, 8, 99237–99244. [CrossRef] [PubMed]

129. Schmitz, R.; Wright, G.W.; Huang, D.W.; Johnson, C.A.; Phelan, J.D.; Wang, J.Q.; Roulland, S.; Kosaka, M.; Young, R.M.; Shaffer, A.L.; et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. *N. Engl. J. Med.* 2018, 378, 1396–1407. [CrossRef] [PubMed]

130. Dalal, B.I.; Keown, P.A.; Greenberg, A.H. Immunohistochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. *Am. J. Pathol.* 1993, 143, 381–389. [PubMed]

131. Friedman, E.; Gold, L.I.; Klimstra, D.; Zeng, Z.S.; Winawer, S.; Cohen, A. High levels of transforming growth factor beta activity by Ki-1 positive lymphoma cells and analysis of its role in the regulation of Ki-1 positive lymphoma growth. *Am. J. Pathol.* 1988, 131, 569–577. [PubMed]
Cancers 2018, 10, 247

141. Newcom, S.R.; Kadin, M.E.; Ansari, A.A.; Diehl, V. L-428 nodular sclerosing Hodgkin’s cell secretes a unique transforming growth factor-beta active at physiologic pH. J. Clin. Investig. 1988, 82, 1915–1921. [CrossRef] [PubMed]

142. Kadin, M.E.; Agnarsson, B.A.; Ellingsworth, L.R.; Newcom, S.R. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin’s disease. Am. J. Pathol. 1990, 136, 1209–1214. [PubMed]

143. Hsu, S.M.; Lin, J.; Xie, S.S.; Hsu, P.L.; Rich, S. Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin’s Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin’s disease. Hum. Pathol. 1993, 24, 249–255. [CrossRef]

144. Maeda, H.; Shiraishi, A. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol. 1996, 156, 73–78. [PubMed]

145. Di Renzo, L.; Altio, A.; Klein, G.; Klein, E. Endogenous TGF-beta contributes to the induction of the EBV lytic cycle in two Burkitt lymphoma cell lines. Int. J. Cancer 1994, 57, 914–919. [CrossRef] [PubMed]

146. Cayrol, C.; Flemington, E.K. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: Activation of transforming growth factor beta isoforms (TGF-beta1 and TGF-beta2) in EBV-positive cells. Exp. Cell Res. 1997, 241, 206–212. [PubMed]

147. Xu, J.; Menezes, J.; Prasad, U.; Ahmad, A. Elevated serum levels of transforming growth factor beta in patients with nasopharyngeal carcinoma. Int. J. Cancer 1999, 84, 396–399. [CrossRef] [PubMed]

148. Hu, C.; Wei, W.; Chen, X.; Woodman, C.B.; Yao, Y.; Nicholls, J.M.; Joab, I.; Sihota, S.K.; Shao, J.Y.; Derkaoui, K.D.; et al. A global view of the oncogenic landscape in nasopharyngeal carcinoma: An integrated analysis at the genetic and expression level. PloS ONE 2012, 7, e41055. [CrossRef] [PubMed]

149. Wang, L.; Tian, W.D.; Xu, X.; Nie, B.; Lu, J.; Liu, X.; Zhang, B.; Dong, Q.; Sunwoo, J.B.; Li, G.; et al. Epstein-Barr virus nuclear antigen 1 (EBNA1) protein induction of epithelial-mesenchymal transition in nasopharyngeal carcinoma cells. Cancer 2014, 120, 363–372. [CrossRef] [PubMed]

150. Naef, M.; Ishiwata, T.; Friess, H.; Buchler, M.W.; Gold, L.I.; Korc, M. Differential localization of transforming growth factor-beta isoforms in human gastric mucosa and overexpression in gastric carcinoma. Int. J. Cancer 1997, 71, 131–137. [CrossRef]

151. Shukla, S.K.; Khatoon, J.; Prasad, K.N.; Rai, R.P.; Singh, A.K.; Kumar, S.; Ghoshal, U.C.; Krishnani, N. Transforming growth factor beta 1 (TGF-β1) modulates Epstein-Barr virus reactivation in absence of Helicobacter pylori infection in patients with gastric cancer. Cytokine 2016, 77, 176–179. [CrossRef] [PubMed]

152. Xu, J.; Lamouille, S.; Derynck, R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009, 19, 156–172. [CrossRef] [PubMed]

153. Wu, Y.; Shen, Z.; Wang, K.; Ha, Y.; Lei, H.; Jia, Y.; Ding, R.; Wu, D.; Gan, S.; Li, R.; et al. High FMNL3 expression promotes nasopharyngeal carcinoma cell metastasis: Role in TGF-beta1-induced epithelia-to-mesenchymal transition. Sci. Rep. 2017, 7, 42507. [CrossRef] [PubMed]

154. Zhou, L.L.; Ni, J.; Feng, W.T.; Yao, R.; Yue, S.; Zhu, Y.N.; Tang, H.Y.; Lv, L.Y.; Feng, J.F.; Zhu, W.G. High YBX1 expression indicates poor prognosis and promotes cell migration and invasion in nasopharyngeal carcinoma. Exp. Cell Res. 2017, 361, 126–134. [CrossRef] [PubMed]

155. Cao, S.; Cui, Y.; Xiao, H.; Mai, M.; Wang, C.; Xie, S.; Yang, J.; Wu, S.; Li, J.; Song, L.; et al. Upregulation of flotillin-1 promotes invasion and metastasis by activating TGF-beta signaling in nasopharyngeal carcinoma. Oncotarget 2016, 7, 42524–4264. [CrossRef] [PubMed]

156. Zhao, L.; Lin, L.; Pan, C.; Shi, M.; Liao, Y.; Bin, J.; Liao, W. Flotillin-2 promotes nasopharyngeal carcinoma metastasis and is necessary for the epithelial-mesenchymal transition induced by transforming growth factor-beta. Oncotarget 2015, 6, 9781–9793. [CrossRef] [PubMed]

157. Xia, Y.Y.; Yin, L.; Jiang, N.; Guo, W.J.; Tian, H.; Jiang, X.S.; Wu, J.; Chen, M.; Wu, J.Z.; He, X. Downregulating HMGA2 attenuates epithelial-mesenchymal transition-induced invasion and migration in nasopharyngeal cancer cells. Biochem. Biophys. Res. Commun. 2015, 463, 357–363. [CrossRef] [PubMed]

158. Du, M.; Chen, W.; Zhang, W.; Tian, X.K.; Wang, T.; Wu, J.; Gu, J.; Zhang, N.; Lu, Z.W.; Qian, L.X.; et al. TGF-beta regulates the ERK/MAPK pathway independent of the SMAD pathway by repressing miRNA-124 to increase MALAT1 expression in nasopharyngeal carcinoma. Biomed. Pharmacother. 2018, 99, 688–696. [CrossRef] [PubMed]

159. Oshimori, N.; Oristian, D.; Fuchs, E. TGF-beta promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 2015, 160, 963–976. [CrossRef] [PubMed]
160. Brunen, D.; Willems, S.M.; Kellner, U.; Midgley, R.; Simon, I.; Bernards, R. TGF-β: An emerging player in drug resistance. *Cell cycle* 2013, 12, 2960–2968. [CrossRef] [PubMed]

161. Bissey, P.A.; Law, J.H.; Bruce, J.P.; Shi, W.; Renoult, A.; Chua, M.L.K.; Yip, K.W.; Liu, F.F. Dysregulation of the MiR-449b target TGFβ1 alters the TGFβ pathway to induce cisplatin resistance in nasopharyngeal carcinoma. *Oncogenesis* 2018, 7, 40. [CrossRef] [PubMed]

162. Wittmann, P.; Hofler, P.; Bauer, G. Epstein-barr virus induction by a serum factor: IV. Ubiquitous occurrence of the factor within vertebrates and its interaction with defined lymphoid cell lines. *Int. J. Cancer* 1982, 30, 503–510. [CrossRef] [PubMed]

163. Chasserot-Golaz, S.; Schuster, C.; Dietrich, J.B.; Beck, G.; Lawrence, D.A. Antagonistic action of RU38486 on the activity of transforming growth factor-β in fibroblasts and lymphoma cells. *J. Steroid Biochem.* 1988, 30, 381–385. [CrossRef]

164. Fahmi, H.; Cochet, C.; Hmama, Z.; Opolon, P.; Joab, I. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway. *J. Virol.* 2000, 74, 5810–5818. [CrossRef] [PubMed]

165. Oussaief, L.; Hippocrate, A.; Ramirez, V.; Rampanou, A.; Zhang, W.; Meyers, D.; Cole, P.; Khelifa, R.; Joab, I. Phosphatidylinositol 3-kinase/Akt pathway targets acetylation of Smad3 through Smad3/CREB-binding protein interaction: Contribution to transforming growth factor beta1-induced Epstein-Barr virus reactivation. *J. Biol. Chem.* 2009, 284, 23912–23924. [CrossRef] [PubMed]

166. Liang, C.L.; Chen, J.L.; Hsu, Y.P.; Ou, J.T.; Chang, Y.S. Epstein-Barr virus BZLF1 gene is activated by transforming growth factor-beta through cooperativity of Smads and c-Jun/c-Fos proteins. *J. Biol. Chem.* 2002, 277, 23345–23357. [CrossRef] [PubMed]

167. Iempridee, T.; Das, S.; Xu, I.; Mertz, J.E. Transforming growth factor beta-induced reactivation of Epstein-Barr virus involves multiple Smad-binding elements cooperatively activating expression of the latent-lytic switch BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters. *Cell cycle* 2013, 12, 2960–2968. [CrossRef] [PubMed]

168. Jiang, D.; Aguiar, R.C. MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-β1/SMAD5 signaling module. *Blood* 2014, 123, 86–93. [CrossRef] [PubMed]
179. Stelling, A.; Hashwah, H.; Bertram, K.; Manz, M.G.; Tzankov, A.; Muller, A. The tumor suppressive TGF-beta/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. Blood 2018, 131, 2235–2246. [CrossRef] [PubMed]

180. Lee, H.M.; Lo, K.W.; Wei, W.; Tsao, S.W.; Chung, G.T.Y.; Ibrahim, M.H.; Dawson, C.W.; Murray, P.G.; Paterson, I.C.; Yap, L.F. Oncogenic S1P signalling in EBV-associated nasopharyngeal carcinoma activates AKT and promotes cell migration through S1P receptor 3. J. Pathol. 2017, 242, 62–72. [CrossRef] [PubMed]

181. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704–715. [CrossRef] [PubMed]

182. Shipitsin, M.; Campbell, L.L.; Argani, P.; Weremowicz, S.; Bloushtain-Qimron, N.; Yao, J.; Nikolskaya, T.; Serebryiskaya, T.; Beroukhim, R.; Guo, B.H.; et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11, 259–273. [CrossRef] [PubMed]

183. Anido, J.; Saez-Borderias, A.; Gonzalez-Junca, A.; Rodon, L.; Folch, G.; Carmona, M.A.; Prieto-Sanchez, R.M.; Barba, I.; Martinez-Saez, E.; Prudkin, L.; et al. TGF-beta Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell 2010, 18, 655–668. [CrossRef] [PubMed]

184. Kondo, S.; Wakisaka, N.; Muramatsu, M.; Zen, Y.; Endo, K.; Murono, S.; Sugimoto, H.; Yamaoka, S.; Pagano, J.S.; Yoshizaki, T. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J. Virol. 2011, 85, 11255–11264. [CrossRef] [PubMed]

185. Kang, J.L.; Hu, L.J.; Cao, J.Y.; Huang, Y.J.; Xu, L.H.; Liang, Y.; Xiong, D.; Guan, S.; Guo, B.H.; Mai, H.Q.; et al. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog. 2010, 6, e1000940. [CrossRef] [PubMed]

186. Akhurst, R.J.; Hata, A. Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov. 2012, 11, 790–811. [CrossRef] [PubMed]

187. Foster, A.E.; Dotti, G.; Lu, A.; Khalil, M.; Brenner, M.K.; Heslop, H.E.; Rooney, C.M.; Bolland, C.M. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J. Immunother. 2008, 31, 500–505. [CrossRef] [PubMed]

188. Zhang, L.; MacIsaac, K.D.; Zhou, T.; Huang, P.Y.; Xin, C.; Dobson, J.R.; Yu, K.; Chiang, D.Y.; Fan, Y.; Pelletier, M.; et al. Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes. Mol. Cancer Res. 2017, 15, 1722–1732. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).